|
The following is a review of diagnostic product developments worldwideThe information is updated the first week of every month - so ... make this a regular stop in your information gathering activities.The following information has been compiled from publicly available sources, StratCom does not assume any responsibility for the accuracy or the authenticity of the information and StratCom cannot be held liable for errors.
Product developments in Summer 2006
Dear Reader, welcome back to the StratCom news update. Sorry for the long absence. It was a very busy summer. Here are some of the highlights. Bayer Diabetes Care, a division of Bayer HealthCare LLC acquired Metrika Inc., a company that manufactures and markets the A1Cnow rapid test meter for HbA1c measurement. Details of the purchase agreement were not disclosed. BD signed a definitive agreement to acquire the 93.5% of the outstanding shares of TriPath Imaging, which BD does not currently own, for a cash purchase price of $9.25 per share, or approximately $350 million. The acquisition is expected to be completed by the end of BD's first fiscal quarter. BD and TriPath Imaging have participated in a collaboration to identify biomarkers for various cancer diagnostics since 2001. BioMedical Diagnostics SA is collaborating with Modules for Novel Diagnostics to develop FIDIS flow cytometer-based assays for the diagnosis of infectious diseases. MND's technology directly measures the presence of live viruses and bacteria in body fluids by detecting the specific enzymatic activity of microorganisms during replication. bioMerieux sold its hemostasis range of products including the MDA, MTX and Thrombolyzer platforms, and reagents to Trinity Biotech. The BioPen Company is developing a BioPen with electro-optics contained in its tip to detect, and identify toxins, bacteria and viruses in fluids including water, biological fluids, blood and urine samples. The BioPen performs an ELISA tests and within 20 minutes displays a digital readout of the result on a small liquid crystal display. Collected data are transmitted to a personal computer (PC) for storage and backup as well as for further analysis. Celerus Diagnostics is designing an instrument for rapid biopsy diagnostics that will provide the capability to decentralize frozen tissue processing. The core technology is a rapid tissue staining system designed for use in histology and cytology testing, including immunohistochemistry. Ciphergen Biosystems, Inc. and Bio-Rad Laboratories, Inc. entered into an agreement for Bio-Rad to acquire Ciphergen's proprietary proteomics instrument business, which includes Ciphergen's Surface Enhanced Laser Desorption/Ionization (SELDI) technology, ProteinChip Arrays and accompanying software. Bio-Rad will purchase this business for approximately $20 million in cash. In addition, Bio-Rad is making a $3 million equity investment in Ciphergen. Diamics Inc. is developing C-MAP, a cervical cancer screening system that examines the behavior of groups of cells within discrete areas of the cervix, allowing lesions to be effectively analyzed in situ. C-MAP technology uses fractional histology, or the microscopic examination of tissue elements characteristic of the disease process. Tissue is collected from the entire cervix in a single process, utilizing a patented single-use collector, which captures a 360-degree view of the cervix and transfers it to a slide. The tissue then is exposed to antibodies and placed in a proprietary optical scanner, which generates a map of the cervix showing the location of precancerous lesions. Fujirebio Diagnostics acquired 100% of the shares and equity-related instruments of CanAg Diagnostics. The combined technologies will be used to develop serum tumor markers. Nova Biomedical launched the Nova StatStrip point-of-care glucose monitor that incorporates four well glucose measuring strip technology. Nova’s Multi-Well system measures and corrects for interferences from oxygen, hematocrit, acetaminophen, uric acid, ascorbic acid, maltose, galactose, xylose, and lactose. Philips Medical Systems entered into a partnership with BG Medicine that gives Philips access to certain BG Medicine proprietary biomarker discovery and validation technologies and associated services for use in patient-centered diagnostics and personalized medicine. As part of the agreement, Philips will take a minority stake in BG Medicine. New company, Prognostics Ltd. was formed by the merger of the University of Cambridge companies SmartBead Technologies Ltd. and FingerPrint Diagnostics Ltd. The company will develop and sell the range of multiplexed diagnostics developed by SmartBead, which initially focused on the area of autoimmune diseases, and will accelerate the development of FingerPrint's CADprint product for the diagnosis of heart disease from a simple blood sample, with a product launch expected in 2008. Roche Diagnostics introduced its apoptosis assay Elisaplus that detects nucleosomes in the cytoplasm of cells prior to disintegration of the plasma membrane. It qualitatively and quantitatively detects the amount of cleaved DNA/histone complexes (nucleosomes) in a given sample using an ELISA method. The Elisaplus kit complements other standard apoptotic assays such as caspase enzymatic assays and immunoblotting, and can replace DNA ladder gels. StatSure Diagnostic Systems, Inc. and Inverness Medical Innovations, Inc. agreed to develop and market consumer diagnostic products for HIV using StatSure's patented barrel technology. IMA will receive an exclusive worldwide license for all consumer markets and a non-exclusive license to market the product to the professional markets.
Product Developments Worldwide | Research News | Health Care in Canada Information Technology and Healthcare | Molecular Biology | Links
![[HRule Image]](images/div.jpg){kind=small} Send mail to stratcom@pagebleu.com with questions or comments about this web site.Concept and Design Blue Page
Productions Last modified: October 25, 2006 |
![[Page Banner Image]](images/hprods.gif){kind=small}
